Marjo Apajasalo

994 total citations
19 papers, 793 citations indexed

About

Marjo Apajasalo is a scholar working on Pediatrics, Perinatology and Child Health, Economics and Econometrics and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Marjo Apajasalo has authored 19 papers receiving a total of 793 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pediatrics, Perinatology and Child Health, 4 papers in Economics and Econometrics and 3 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Marjo Apajasalo's work include Childhood Cancer Survivors' Quality of Life (4 papers), Health Systems, Economic Evaluations, Quality of Life (4 papers) and Heart Failure Treatment and Management (3 papers). Marjo Apajasalo is often cited by papers focused on Childhood Cancer Survivors' Quality of Life (4 papers), Health Systems, Economic Evaluations, Quality of Life (4 papers) and Heart Failure Treatment and Management (3 papers). Marjo Apajasalo collaborates with scholars based in Finland, United Kingdom and United States. Marjo Apajasalo's co-authors include J. Rautonen, Harri Sintonen, Christer Holmberg, Martti A. Siimes, Ilkka Kaitila, Annikki Mäkelä, Veikko Aalberg, Helena Pihko, Janne Sinkkonen and Raija Anttila and has published in prestigious journals such as The Lancet, SHILAP Revista de lepidopterología and European Journal of Cancer.

In The Last Decade

Marjo Apajasalo

19 papers receiving 747 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Marjo Apajasalo Finland 14 374 139 138 129 125 19 793
Maria-Dolors Estrada Spain 8 273 0.7× 86 0.6× 188 1.4× 36 0.3× 72 0.6× 13 933
Julia E. Richerson United States 11 200 0.5× 100 0.7× 127 0.9× 60 0.5× 32 0.3× 13 832
Stefan Essig Switzerland 16 329 0.9× 71 0.5× 289 2.1× 33 0.3× 149 1.2× 57 803
Alexy D. Arauz Boudreau United States 10 184 0.5× 92 0.7× 156 1.1× 44 0.3× 35 0.3× 11 783
Graham A. Barden United States 7 170 0.5× 79 0.6× 143 1.0× 44 0.3× 27 0.2× 8 765
Mary Lynn Brecht United States 10 145 0.4× 60 0.4× 143 1.0× 251 1.9× 106 0.8× 15 949
Amy Peykoff Hardin United States 8 176 0.5× 81 0.6× 151 1.1× 44 0.3× 27 0.2× 8 786
Vivian T. Colland Netherlands 17 185 0.5× 185 1.3× 45 0.3× 249 1.9× 55 0.4× 22 891
Margaret McCabe United States 14 153 0.4× 61 0.4× 180 1.3× 85 0.7× 29 0.2× 43 658
Mariella Lane United States 8 411 1.1× 143 1.0× 76 0.6× 37 0.3× 64 0.5× 10 803

Countries citing papers authored by Marjo Apajasalo

Since Specialization
Citations

This map shows the geographic impact of Marjo Apajasalo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marjo Apajasalo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marjo Apajasalo more than expected).

Fields of papers citing papers by Marjo Apajasalo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marjo Apajasalo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marjo Apajasalo. The network helps show where Marjo Apajasalo may publish in the future.

Co-authorship network of co-authors of Marjo Apajasalo

This figure shows the co-authorship network connecting the top 25 collaborators of Marjo Apajasalo. A scholar is included among the top collaborators of Marjo Apajasalo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marjo Apajasalo. Marjo Apajasalo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Rissanen, A., Harri Sintonen, Risto P. Roine, et al.. (2019). COMPARATIVE STUDY OF HEALTH-RELATED QUALITY OF LIFE AMONG FINNISH 12- TO 15-YEAR-OLD ADOLESCENTS IN 1996 AND 2013. SHILAP Revista de lepidopterología. 1 indexed citations
2.
Turunen, Heidi, Stephan M. Jakob, Esko Ruokonen, et al.. (2015). Dexmedetomidine versus standard care sedation with propofol or midazolam in intensive care: an economic evaluation. Critical Care. 19(1). 67–67. 47 indexed citations
3.
Kivikko, Matti, et al.. (2015). Cost-benefits of incorporating levosimendan into cardiac surgery practice: German base case. Journal of Medical Economics. 19(5). 506–514. 5 indexed citations
4.
Lucioni, Carlo, et al.. (2012). Economic Evaluation of Levosimendan Versus Dobutamine for the Treatment of Acute Heart Failure in Italy. Advances in Therapy. 29(12). 1037–1050. 13 indexed citations
5.
Sipilä, Ilkka, et al.. (2010). Long‐term effects of growth hormone therapy on patients with Prader–Willi syndrome. Acta Paediatrica. 99(11). 1712–1718. 23 indexed citations
6.
Findley, Leslie J., et al.. (2005). Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off. Current Medical Research and Opinion. 21(7). 1005–1014. 22 indexed citations
7.
Johansson, Susanne, Marjo Apajasalo, Toni Sarapohja, & Chris Garratt. (2004). Effect of levosimendan treatment on length of hospital and intensive care stay in the REVIVE I study. Critical Care. 8(Suppl 1). P88–P88. 10 indexed citations
8.
Qvist, Erik, Vesa Närhi, Marjo Apajasalo, et al.. (2004). Psychosocial adjustment and quality of life after renal transplantation in early childhood. Pediatric Transplantation. 8(2). 120–125. 60 indexed citations
9.
Cleland, John G.F., A. Takala, Marjo Apajasalo, Niklas Zethraeus, & Gisela Kobelt. (2003). Intravenous Levosimendan Treatment is Cost-Effective Compared with Dobutamine in Severe Low-Output Heart Failure: An Analysis Based on the International LIDO Trial. European Journal of Heart Failure. 5(1). 101–108. 35 indexed citations
10.
Sintonen, Harri, et al.. (2003). Measuring health-related quality of life in women on hormone replacement therapy. Expert Review of Pharmacoeconomics & Outcomes Research. 3(3). 351–361. 6 indexed citations
11.
Linna, Miika, et al.. (2002). Probabilistic sensitivity analysis for evaluating cost-utility of entacapone for Parkinson’s disease. Expert Review of Pharmacoeconomics & Outcomes Research. 2(2). 91–97. 13 indexed citations
12.
13.
Apajasalo, Marjo, Harri Sintonen, J. Rautonen, & Ilkka Kaitila. (1998). Health-related quality of life of patients with genetic skeletal dysplasias. European Journal of Pediatrics. 157(2). 114–121. 35 indexed citations
14.
Apajasalo, Marjo, et al.. (1997). Health-related quality of life after organ transplantation in childhood.. PubMed. 1(2). 130–7. 40 indexed citations
15.
Apajasalo, Marjo, Harri Sintonen, Martti A. Siimes, et al.. (1996). Health-related quality of life of adults surviving malignancies in childhood. European Journal of Cancer Prevention. 1354–1358. 3 indexed citations
16.
Apajasalo, Marjo, Harri Sintonen, Christer Holmberg, et al.. (1996). Quality of life in early adolescence: A sixteendimensional health-related measure (16D). Quality of Life Research. 5(2). 205–211. 150 indexed citations
17.
Apajasalo, Marjo, Harri Sintonen, Martti A. Siimes, et al.. (1996). Health-related quality of life of adults surviving malignancies in childhood. European Journal of Cancer. 32(8). 1354–1358. 74 indexed citations
18.
Apajasalo, Marjo, J. Rautonen, Christer Holmberg, et al.. (1996). Quality of life in pre-adolescence: A 17-dimensional health-related measure (17D). Quality of Life Research. 5(6). 532–538. 126 indexed citations
19.
Rautonen, J., et al.. (1994). CRIB and SNAP: assessing the risk of death for preterm neonates. The Lancet. 343(8908). 1272–1273. 78 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Maria-Dolors Estrada Breakdown of academic impact, for papers by Julia E. Richerson Breakdown of academic impact, for papers by Stefan Essig Breakdown of academic impact, for papers by Alexy D. Arauz Boudreau Breakdown of academic impact, for papers by Graham A. Barden Breakdown of academic impact, for papers by Mary Lynn Brecht Breakdown of academic impact, for papers by Amy Peykoff Hardin Breakdown of academic impact, for papers by Vivian T. Colland Breakdown of academic impact, for papers by Margaret McCabe Breakdown of academic impact, for papers by Mariella Lane
Rankless by CCL
2026